Fidelity Select Biotechnology Portfolio
FBIOX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Fidelity Select Portfolios MA United States of America
- IPO Date
- Dec 16, 1985
- CIK
- 0000320351
- Website
- fundresearch.fidelity.com
- Similar Companies
- Business
- Fidelity Select Biotechnology Portfolio (FBIOX) is an actively managed open-end mutual fund that normally invests at least 80% of its assets in securities of companies principally engaged in the research, development, manufacture, and sale of various biotechnological products, services, and processes; these include companies involved in gene therapy, genetic modeling, pharmacogenomics, and drug discovery platforms. The portfolio provides exposure to biotechnology equities through holdings such as AbbVie Inc. (ABBV), Amgen Inc. (AMGN), Krystal Biotech Inc. (KRYS), and Vertex Pharmaceuticals Inc. (VRTX), with additional allocations to cash equivalents like the Fidelity Securities Lending Cash Central Fund. It targets institutional and retail investors seeking sector-specific growth in the healthcare and life sciences industries, primarily in the United States market. Launched in 2000 and managed by Fidelity Investments, headquartered in Boston, Massachusetts, the fund operates under Fidelity's Select Portfolios series with a CUSIP of 316390772 and focuses on non-diversified investments within the Morningstar Health category. Geographically, it concentrates on U.S.-listed securities while maintaining liquidity through short-term instruments. In recent developments as of 2025, the fund added new positions including Phathom Pharmaceuticals Inc., reflecting portfolio rebalancing amid sector opportunities; for the semiannual period ending August 31, 2025, it delivered a 4.77% gain, outperforming the MSCI U.S. IMI Biotechnology 25/50 Index's 1.16% return. Portfolio management updates include commentary from August 31, 2025, highlighting strategic adjustments in holdings and sector weights, with no major mergers, funding rounds, or reorganizations reported in the last 1-2 years. The expense ratio remains competitive at levels typical for sector funds, supporting ongoing investor access.